期刊文献+

32例活动期寻常型天疱疮患者血清免疫球蛋白G4水平分析

Serum Immunoglobulin G4 Level in 32 Patients with Active-phase Pemphigus Vulgaris
原文传递
导出
摘要 目的通过检测活动期寻常型天疱疮(PV)患者血清免疫球蛋白(Ig)G4浓度,了解IgG4在活动期PV患者血清中的水平。方法收集2014年4月-12月处于活动期(包括急性起始阶段和慢性活动期)的PV患者血清,通过免疫散射比浊法测定其血清IgG4水平,并比较PV患者和正常人群、急性起始阶段和慢性活动期患者间血清IgG4水平的差异。结果入选了32例活动期PV患者,血清IgG4在正常范围内的患者共有22例,其中男8例,女14例;IgG4升高8例,男3例,女5例;血清IgG4水平下降2例,男女各1例。32例患者与正常人群血清IgG4水平平均值比较,差异无统计学意义(P>0.05)。急性起始阶段PV患者血清IgG4浓度为(1.015±0.825)g/L,慢性活动期PV患者血清IgG4浓度为(1.058±1.133)g/L,两组间比较差异无统计学意义(P>0.05)。结论活动期PV患者的血清IgG4水平可以在正常范围内,也可以升高或降低;而IgG4水平在急性起始阶段和慢性活动期无明显变化。 ObjectiveTo learn the serum immunoglobulin G4 (IgG4) level in patients with pemphigus vulgaris (PV) in the active phase by detecting the IgG4 concentration in the patients with PV. MethodsWe collected the serum samples from patients with active-phase PV (including acute-onset and chronic active phases) between April and December 2014. The serum IgG4 level was detected by immuno-scatter turbidmetry, and the difference of serum IgG4 level between PV patients and normal subjects was assessed by Student's t-test. ResultsThirty-two patients with pemphigus vulgaris in the active phase were enrolled for this study, among whom 22 (including 8 males and 14 females) had normal serum IgG4 level, 8 (including 3 males and 5 females) higher and 2 (including 1 male and 1 female) lower. Compared with normal subjects, the average level of serum IgG4 in PV patients was not significantly different (P〉0.05). The serum IgG4 level of acute-onset and chronic active PV patients was (1.015±0.825) g/L and (1.058±1.133) g/L, respectively, with no significant difference (P〉0.05). ConclusionThe serum IgG4 level of patients with pemphigus vulgaris in the active phase can be normal, higher or lower. And there is no obvious difference in the serum IgG4 level between acute-onset and chronic active PV patients.
出处 《华西医学》 CAS 2016年第11期1822-1825,共4页 West China Medical Journal
关键词 寻常型天疱疮 免疫球蛋白G4 免疫散射比浊法 Pemphigus vulgaris Immunoglobulin G4 Immuno-scatter turbidmetry
  • 相关文献

参考文献3

二级参考文献50

  • 1Takayoshi Fujita,Takafumi Ando,Masatoshi Sakakibara,Waki Hosoda,Hidemi Goto.Refractory gastric ulcer with abundant IgG4-positive plasma cell infiltration: A case report[J].World Journal of Gastroenterology,2010,16(17):2183-2186. 被引量:13
  • 2Johnson P,Glennie M.The mechanisms of action of rituximab in the elimination of tumor cells[J].Semin Oncol,2003,30(1 Suppl 2):3-8.
  • 3Ghetie MA,Bright H,Vitetta ES.Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin[J].Blood,2001,97(5):1392-1398.
  • 4Pfreundschuh M,Kuhnt E,Trümper L,et al.CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma:6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group[J].Lancet Oncol,2011,12(11):1013-1022.
  • 5Fowler N,Kahl BS,Lee P,et al.Bortezomib,bendamustine,and rituximab in patients with relapsed or refractory follicular lymphoma:the phase II VERTICAL study[J].J Clin Oncol,2011,29(25):3389-3395.
  • 6Tobinai K,Igarashi T,Itoh K,et al.Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab:a multicenter phase II study[J].Cancer Sci,2011,102(9):1698-1705.
  • 7Byrd JC,Rai K,Peterson BL,et al.Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia:an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011[J].Blood,2005,105(1):49-53.
  • 8Robak T,Dmoszynska A,Solal-Céligny P,et al.Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia[J].J Clin Oncol,2010,28(10):1756-1765.
  • 9Zaja F,Vianelli N,Volpetti S,et al.Low-dose rituximab in adult patients with primary immune thrombocytopenia[J].Eur J Haematol,2010,85(4):329-334.
  • 10Pasa S,Altintas A,Cil T,et al.The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura[J].J Thromb Thrombolysis,2009,27(3):329-333.

共引文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部